SOURCE: Lipid Sciences, Inc.

October 11, 2006 08:30 ET

Lipid Sciences, Inc. HDL Selective Delipidation Technology Represented at the New York Advances in Cardiac Endovascular Therapies (ACE) Meeting

Dr. H. Bryan Brewer, Jr. and Dr. Ron Waksman Presenters

PLEASANTON, CA -- (MARKET WIRE) -- October 11, 2006 -- Lipid Sciences, Inc. (NASDAQ: LIPD) announced that the Company's HDL Selective Delipidation technology platform was represented at presentations and workshops conducted at the New York ACE Meeting, a prestigious cardiovascular care conference held October 8-11. Presentations were made by: Dr. H. Bryan Brewer, Jr., Lipid Sciences' Vice Chairman, Chief Scientific Director, and member of the Lipid Sciences Board of Directors; and Dr. Ron Waksman, Director, Experimental Angioplasty and New Technologies, Cardiovascular Institute, and Associate Director, Division of Cardiology, Washington Hospital Center, and Principal Investigator for Lipid Sciences' "first in man" clinical trial for HDL Selective Delipidation.

New York ACE is a unique combination of live demonstration cases, lectures, focused workshops, case review sessions, and simulator training offered by a renowned faculty of nationally and internationally acknowledged experts in the fields of interventional cardiology, vascular and cardiovascular surgery, interventional radiology, and cardiothoracic surgery. The meeting is designed to meet the needs of all physicians, nurses and other healthcare professionals interested in the interventional management of patients with heart and vascular disease. Also in attendance were financial analysts looking to sharpen their cardiovascular disease market focus and identify key trends and company players with cutting edge participation in that space.

Further details about the program can be found at

Presentation Topics Included:

Dr. H. Bryan Brewer, Jr.: New Approaches to Acute Coronary Syndrome - Delipidation/Stabilization of Vulnerable Plaque; and Chronic Total Occlusions (CTO's) and Vulnerable Plaque.

Dr. Ron Waksman: High-Density Lipoprotein (HDL) Apheresis for Vulnerable Plaque Modification.

Background Information:

Dr. H. Bryan Brewer, Jr. is the Director of Lipoprotein and Atherosclerosis Research at the Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center in Washington, D.C. Dr. Brewer was the Chief of the Molecular Disease Branch at the National Heart, Lung, and Blood Institute, National Institutes of Health in Bethesda, Maryland for 29 years. He is a world-recognized authority in the field of lipid metabolism and cardiovascular disease research. His early research led to the first published sequences for human plasma apolipoproteins, the initial determination of plasma apolipoprotein metabolism in normal and hyperlipidemic individuals, and the identification of multiple gene defects leading to genetic dyslipoproteinemias. Dr. Brewer pioneered the use of transgenic mice and rabbits, as well as recombinant adenovirus vectors to identify genes that modulate lipoprotein metabolism and the development of atherosclerosis.

Dr. Brewer is Vice Chairman, Chief Scientific Director, a member of the Board of Directors and the Scientific Advisory Board of Lipid Sciences, Inc.

Dr. Ron Waksman is the Director, Experimental Angioplasty and New Technologies, Cardiovascular Research Institute, and Associate Director, Division of Cardiology, Washington Hospital Center, Washington, D.C. Dr. Waksman is an interventional cardiologist. He is the editor of three books in the field of cardiovascular radiation medicine, and has more than 50 peer-reviewed manuscripts published in professional journals on that subject and has been conducting extensive pre-clinical and clinical research in this field.

Dr. Waksman is the Principal Investigator for the Lipid Sciences "first in man" clinical trial: "A Randomized Single-Blind Placebo Controlled Study to Evaluate the Safety of the Lipid Sciences Plasma Delipidation System (PDS-2) in Subjects with Prior Acute Coronary Syndrome" which is currently being conducted at the Washington Hospital Center, Washington, D.C.

For further information regarding Lipid Sciences' HDL Selective Delipidation, please visit the Company website at:

Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes intended to treat major medical indications, in which lipids, or fat components, play a key role. The Company's HDL Therapy platform (HDL Selective Delipidation and HDL mimetic peptides) is aimed at developing treatments for the reversal of atherosclerosis, a systemic disease of the blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The Company's Viral Immunotherapy platform is focused on the removal of the lipid coatings from lipid-enveloped viruses and other lipid-containing infectious agents by application of Lipid Sciences' proprietary delipidation technology. The Company believes that removing the virus' protective lipid coating enhances the processing and presentation of viral proteins to stimulate the body's immune system to effectively fight the disease. Conditions that could potentially be impacted by this technology include HIV, Hepatitis B and Hepatitis C, West Nile, SARS and influenza.

Forward-Looking Statements: This release contains forward-looking statements concerning plans, objectives, goals, strategies, study results, anticipations, expectations, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers are referred to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: Our inability to obtain adequate funds; the significant losses we have incurred to date, and our expectation that we will incur substantial losses in the future; the failure of our technology to prove safe or effective; our inability to obtain regulatory approval for our technology, which is only in the clinical development stage; delay or failure to complete clinical studies; our dependence on our license agreement with Aruba International B.V.; our reliance on collaborations with strategic partners and consultants; competition in our industry, including the development of new products by others that may provide alternative or better therapies; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; acceptance of our potential products by healthcare providers and patients; our exposure to product liability claims; and our dependence on key personnel.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.

Press releases for Lipid Sciences, Inc. are available on our website: If you would like to receive our press releases via email, please contact:

Contact Information

    Deborah S. Lorenz
    Vice President, Investor Relations and
    Corporate Communications
    Lipid Sciences, Inc.
    Email Contact